Get the Stockscreener App
2.06
0.90%
-0.0188
After Hours:
2.05
-0.01
-0.49%
Pulmatrix Inc stock is traded at $2.06, with a volume of 17,808.
It is down -0.90% in the last 24 hours and down -1.90% over the past month.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
See More
Previous Close:
$2.0788
Open:
$2.06
24h Volume:
17,808
Relative Volume:
1.55
Market Cap:
$7.52M
Revenue:
$11.68M
Net Income/Loss:
$-8.85M
P/E Ratio:
-0.4247
EPS:
-4.85
Net Cash Flow:
$-14.61M
1W Performance:
-5.50%
1M Performance:
-1.90%
6M Performance:
+5.10%
1Y Performance:
+7.85%
1-Day Range:
$2.03
$2.1728
1-Week Range:
$2.03
$2.28
52-Week Range:
$1.55
$2.7499
Pulmatrix Inc Stock (PULM) Company Profile
Name
Pulmatrix Inc
Sector
Industry
Phone
(888) 355-4440
Address
945 CONCORD STREET, FRAMINGHAM, MA
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-18 | Initiated | H.C. Wainwright | Buy |
Pulmatrix Inc Stock (PULM) Latest News
Head-To-Head Contrast: Sage Therapeutics (NASDAQ:SAGE) and Pulmatrix (NASDAQ:PULM) - Defense World
Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com - Defense World
Pulmatrix sets date for 2024 annual stockholders meeting By Investing.com - Investing.com South Africa
Pulmatrix sets date for 2024 annual stockholders meeting - Investing.com India
StockNews.com Begins Coverage on Pulmatrix (NASDAQ:PULM) - Defense World
Reviewing Pulmatrix (NASDAQ:PULM) & Emergent BioSolutions (NYSE:EBS) - Defense World
Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update - Defense World
Pulmatrix (NASDAQ:PULM) Now Covered by Analysts at StockNews.com - Defense World
Pulmatrix (NASDAQ:PULM) Receives New Coverage from Analysts at StockNews.com - Defense World
Pulmatrix (NASDAQ:PULM) Shares Pass Above Fifty Day Moving Average of $2.10 - Defense World
Pulmatrix (NASDAQ:PULM) Stock Price Crosses Above Fifty Day Moving Average of $2.08 - Defense World
Pulmatrix Second Quarter 2024 Earnings: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023) - Yahoo Finance
Pulmatrix (NASDAQ:PULM) Shares Pass Above 50-Day Moving Average of $2.06 - Defense World
PULM stock touches 52-week high at $2.75 amid market fluctuations - Investing.com
StockNews.com Initiates Coverage on Pulmatrix (NASDAQ:PULM) - Defense World
PULM Stock Earnings: Pulmatrix Reported Results for Q2 2024 - InvestorPlace
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update - Quantisnow
Pulmatrix (NASDAQ:PULM) Research Coverage Started at StockNews.com - American Banking and Market News
There Is A Reason Pulmatrix, Inc.'s (NASDAQ:PULM) Price Is Undemanding - Simply Wall St
Global Respiratory Devices Market 2024 Analysis by Top Key Players |3b Medical Inc., Pulmatrix Inc. - The NRI News
Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com - Defense World
Pulmatrix Announces Executive Changes and New Interim CEO - TipRanks
Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Up 120.0% in June - Defense World
Pulmatrix (NASDAQ:PULM) Stock Crosses Above 50 Day Moving Average of $1.92 - Defense World
Pulmatrix, Inc. (PULM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Yahoo New Zealand News
Who Owns Most Of Pulmatrix Inc (NASDAQ:PULM)? - Yahoo Movies UK
Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering - Quantisnow
Pulmatrix appoints Director Anand Varadan - Quantisnow
Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update - Quantisnow
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update - Quantisnow
Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline - Quantisnow
Pulmatrix Announces $6.75 Million Registered Direct Offering - Quantisnow
Pulmatrix Announces Resolution of Contract Dispute with Cipla - Quantisnow
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Quantisnow
Reading International (NASDAQ:RDI) Coverage Initiated at StockNews.com - Defense World
Pure Storage (NYSE:PSTG) Shares Gap Up After Analyst Upgrade - Defense World
Pulmatrix Inc (PULM)'s Ratio Roundup: Key Metrics for Trailing Twelve Months – DWinneX - The Dwinnex
MannKind expands R&D with Pulmatrix technology exchange - Investing.com India
MannKind expands R&D with Pulmatrix technology exchange By Investing.com - Investing.com Canada
Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Sport Australia
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation - PR Newswire
Amicus Therapeutics (FOLD) Reports Q3 Loss, Misses Revenue Estimates - Yahoo New Zealand News
Teacher Retirement System of Texas Has $1.58 Million Stock Holdings in Polaris Inc. (NYSE:PII) - Defense World
Pulmatrix reports progress in migraine treatment study By Investing.com - Investing.com
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine ... - PR Newswire
Pulmatrix Publishes Study on Inhalable Migraine TreatmentTipRanks.com - TipRanks
Pulmatrix Inc Stock (PULM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):